Stock Screener App

Frei -

Installieren

11.27

2.45% 0.27

after-market

Handel nachbörslich: 11.46 0.19 +1.69%

Mink Therapeutics Inc (INKT)

Überblick Nachrichten Preisverlauf Financials Forum Prognose

Schlusskurs vom Vortag:

$11.00

Offen:

$11.1

24-Stunden-Volumen:

6,786

Relative Volume:

0.27

Marktkapitalisierung:

$56.15M

Einnahmen:

-

Nettoeinkommen (Verlust:

$-12.49M

KGV:

-3.8013

EPS:

-2.9648

Netto-Cashflow:

$-5.93M

1W Leistung:

+2.92%

1M Leistung:

-1.23%

6M Leistung:

+2.08%

1J Leistung:

-26.44%

1-Tages-Spanne:

$10.95

$11.50

1-Wochen-Bereich:

$10.80

$11.60

52-Wochen-Spanne:

$8.4801

$18.17

Mink Therapeutics Inc Stock (INKT) Company Profile

Firmenname

Mink Therapeutics Inc

Sektor

Healthcare (1080)

Branche

Biotechnology (604)

Telefon

212-994-8250

Adresse

149 FIFTH AVENUE, NEW YORK

Mitarbeiter

15

Twitter

Nächster Verdiensttermin

2026-08-13

Neueste SEC-Einreichungen

INKT's Discussions on Twitter

Compare INKT vs VRTX, REGN, ARGX, RVMD, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
INKT Mink Therapeutics Inc	11.27	56.59M	0	-12.49M	-5.93M	-2.9648
VRTX Vertex Pharmaceuticals Inc	505.75	133.25B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	803.48	82.16B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	851.29	54.80B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	203.71	43.99B	742.00K	-1.37B	-1.07B	-7.0731
ONC Beone Medicines Ltd Adr	347.48	40.62B	5.76B	514.49M	1.10B	4.4813

Mink Therapeutics Inc Stock (INKT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-08-15	Hochstufung	H.C. Wainwright	Neutral → Buy
2025-07-14	Herabstufung	William Blair	Outperform → Mkt Perform

Mink Therapeutics Inc Aktie (INKT) Neueste Nachrichten

MiNK Therapeutics Q2 2026 Earnings Call: Complete Transcript - Sahm

H.C. Wainwright Maintains MiNK Therapeutics(INKT.US) With Buy Rating, Maintains Target Price $35 - moomoo.com

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research - marketbeat.com

MiNK Therapeutics (INKT) Q2 2026 Earnings Call Transcript - AOL.com

MiNK Therapeutics (NASDAQ:INKT) Releases Quarterly Earnings Results, Misses Estimates By $0.02 EPS - marketbeat.com

MiNK Therapeutics, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

MiNK Therapeutics, Inc. (INKT) Presents at 2026 Military Health System Research SymposiumSlideshow - Seeking Alpha

MiNK Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

META_TITLE_QUOTE - Yahoo Finance

MiNK Therapeutics Q2 Earnings Call Highlights - MarketBeat

MiNK Therapeutics Q2 Results: Net loss narrows to $3.1M, cash at $8.8M - scanx.trade

INKT: Advanced phase II ARDS trial and global access for agenT-797, with stable financials - TradingView

MiNK Therapeutics (INKT.US) will release its earnings report after market close on August 13. - 富途牛牛

Earnings call transcript: MiNK Therapeutics narrows Q2 2026 loss as trial advances - Investing.com

Transcript : MiNK Therapeutics, Inc., Q2 2026 Earnings Call, Aug 13, 2026 - marketscreener.com

INKT: Phase II trial for agenT-797 in ARDS shows early promise; global access and financial discipline maintained - TradingView

MiNK Therapeutics Reports Second Quarter 2026 Financial Results and Reports Observations from Randomized Phase 2 Trial of agenT-797 in Acute Lung Injury - Investing News Network

Form 8K Mink Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria

MiNK Therapeutics reports Phase 2 trial data for agenT-797 By Investing.com - Investing.com Australia

MiNK Therapeutics reports Phase 2 trial data for agenT-797 - Investing.com

MiNK Reports $3.1 Million Second-Quarter Loss and Phase 2 ARDS Update - Quiver Quantitative

MiNK Therapeutics Q2 loss narrows on expense discipline - TradingView

Mink Therapeutics Inc (INKT) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey

Mink Therapeutics Inc expected to post a loss of 60 cents a shareEarnings Preview - TradingView

MiNK Therapeutics to Report Second Quarter 2026 Financial Results, Provide Clinical Updates on agenT-797 in Lung Injury, and Highlight Important Business Updates - Investing News Network

MiNK Therapeutics, Inc. (INKT) Stock: Climbs on Encouraging Phase 2 Data for agenT-797 in Severe Pneumonia - Blockonomi

Transactions récentes par des initiés de Mink Therapeutics Inc. R (6Q40.F) - Yahoo Finance France

MiNK Therapeutics Presents Early Observations from Ongoing Phase 2 Trial at the 2026 Military Health System Research Symposium - GlobeNewswire

Liquidity Mapping Around (INKT) Price Events - Stock Traders Daily

MiNK Therapeutics to Report Second Quarter 2026 Financial Results and Provide Corporate Update on agenT-797 Clinical Progress - Quiver Quantitative

MiNK Therapeutics to Report Second Quarter 2026 Financial - GlobeNewswire

New agenT-797 lung-injury data due from MiNK Aug. 13 - Stock Titan

MiNK Therapeutics (INKT) Projected to Post Earnings on Thursday - MarketBeat

Mink Therapeutics to report Q2 results, host conference call and webcast - Bitget

INKT Q2'26 Earnings: revenue estimate is 0 USD - TradingView

MiNK Therapeutics (INKT) Climbs 5.7% as Biotech Momentum BuildsStraddle Setup - dars.gov.et

MiNK Therapeutics Q1 2026 Earnings: Narrower Loss than Expected Reflects Cost DisciplineQuarterly Earnings - dars.gov.et

Mink Therapeutics Inc (INKT) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey

Mink Therapeutics Inc (INKT) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey

Mink Therapeutics Inc (INKT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com

Mink Therapeutics Inc (INKT) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey

INKT|Mink Therapeutics Inc|Price:11.070|Chg%:+0.700 - TradingKey

TradingKey - TradingKey

Mink Therapeutics Inc (INKT) Balance Sheet - TradingKey

Mink Therapeutics Inc (INKT) Income Statement - TradingKey

MiNK Therapeutics, Inc. Revenue Breakdown – FWB:6Q40 - TradingView

Mink Therapeutics Inc (INKT) Valuation: PE, PB & Fair Value Analysis - TradingKey

Mink Therapeutics Inc (INKT) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey

MiNK Therapeutics, Inc. Revenue Breakdown – MUN:6Q40 - TradingView

INKT|Mink Therapeutics Inc|Price:10.600|Chg%:-0.470 - TradingKey

INKT|Mink Therapeutics Inc|Price:11.310|Chg%:+0.620 - TradingKey

Finanzdaten der Mink Therapeutics Inc-Aktie (INKT)

Umsatz

Nettogewinn

Free Cashflow

ENV

MRNA

$63.32

0.52%

RPRX

$58.60

0.07%

ROIV

$36.20

0.22%

INSM

$123.74

2.05%

ALNY

$228.65

0.67%

ONC

$347.48

2.40%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters